Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies - Body, JJ; Diel, IJ; Lichinitzer, M (Br J Cancer, 2004)
et al.